Hyperglycemia is commonly manifested in cancer patients. Although high intakes of sugar and refined carbohydrates and elevated blood glucose are strongly associated with the risk of cancer, much less is known about their effects on survival after cancer diagnosis. There is evidence that high carbohydrate intake is associated with poorer survival after diagnosis for early breast cancer. We measured glycated hemoglobin in a group of cancer patients (some with active disease and some in remission) and found a statistically significant lower average blood glucose in those in remission. Glycated hemoglobin provides an indication of average blood glucose over 2 to 3 months. The authors discuss lifestyle changes including diet and physical activity that can reduce average blood glucose. Ascorbic acid (AA) supplementation as an adjunct to cancer therapy is also considered. Furthermore, they present a biologically plausible explanation for how hyperglycemia can impair the actions of AA and damage immune effectiveness and hinder cancer survival. One mechanism is likely a reduction in intracellular AA; high intracellular levels of AA are necessary for optimal activity of the hexose monophosphate shunt. This metabolic pathway is important for maintaining proper cellular antioxidant status in immune cells including lymphocytes involved in cell-mediated immunity.
Impaired glucose tolerance is a common observation in cancer patients. [1] [2] [3] [4] [5] [6] In 1885, Freund reported 62 of 70 cancer patients exhibited hyperglycemia. 1 In a study of 850 consecutive cases, a hyperglycemic response (blood glucose maximum >200 mg/dL) occurred more than 3 times more frequently in cancer patients than in age-matched controls. 2 About 70% of patients with pancreatic cancer have an impaired glucose tolerance for which the mechanism of the abnormal glucose metabolism is not known. 6 High intake of refined sugars is associated with abnormal glucose tolerance, 7 and cancer mortality is strongly correlated with the level of dietary sugar intake; countries with the greatest per capita sugar intake exhibit the highest rates of breast cancer mortality independent of other variables. 8, 9 In contrast, there is much evidence that caloric restriction reduces both average blood glucose and the susceptibility to neoplastic disease. Since the time of Galen, it has been observed that tumors grow poorly or not at all in underfed animals. Sixty years ago, calorically restricted animals were shown to exhibit marked resistance to tumors. [10] [11] [12] Alteration of dietary compositions showed that the effect was not due to reduced intake of protein or other essential nutrients. 12 Numerous subsequent animal and human studies have clearly established the association of caloric restriction and reduction in cancer incidence. [13] [14] [15] Moreover, there is a link between the lowering of blood glucose and remission of malignancy. Patients under insulin coma therapy for 6 months (for psychosis) were reported to become free of large tumor burdens considered incurable by their oncologists. 16 In a study of 24 tumor patients, the 5 whose glucose tolerance improved were the only ones achieving sustained remission from their malignancy. 17 The effectiveness of conventional radiation for cervical carcinoma was enhanced several-fold when dietary sugar was prohibited. 18 In a murine model of breast cancer, we showed that mortality correlated with average blood glucose; that is, the highest average blood glucose resulted in the highest mortality. 19 In that study, average blood glucose was measured as glycated hemoglobin (GHb). The GHb assay provides a simple, economical, and accurate assessment of average blood glucose over the previous 2 to 3 months.
In this article, we discuss (1) GHb in cancer patients, (2) lifestyle changes for glycemic control in cancer patients, (3) ascorbic acid (AA) as an adjunct to cancer therapy, and (4) a mechanism by which
GHb in Cancer Patients
A search of the National Library of Medicine's PubMed database using the search terms cancer and hyperglycemia produced a list of more than 950 citations. Fewer than 80 articles were found using the terms cancer and glycated hemoglobin. However, when the search was narrowed, using cancer, hyperglycemia, and glycated hemoglobin, only 5 publications involving human subjects were retrieved. Thus, little has been published on the relationship of this important measure of glycemic control and the outcome in cancer patients. We measured GHb and plasma AA in 46 patients with either active malignant disease or in remission or with benign tumors ( Table 1 ). The study protocol was approved by the Human Subjects Review Committee of the Northwest Oncology Foundation.
More than 1000 tumor patients (63% female and 37% male) who have achieved sustained remission were seen periodically for routine follow-up at the Northwest Oncology Clinic, in Seattle, Washington. These and all new active disease patients arriving on the days of research specimen collection were invited to participate. There was no recruiting of patients for the research; patients were taken in sequence. Informed consent was obtained, and all consenting patients were asked to provide routine information about their diet and customary vitamin supplement regimens. Patients consuming 2 g AA daily or less are reported here; AA supplementation at high levels (eg, >10 g/d) is likely to inhibit in vivo glycation and interfere with GHb assays. 20, 21 Breast cancer (3 active disease and 5 remission) and melanoma (2 active disease and 7 remission) comprised 40% of the malignancies in the study group. Colorectal, lung, and renal cell cancer and non-Hodgkin lymphoma totaled another 32%. Sarcoma, urothelial, and gynecological cancers were also observed. Tumor types appeared to be approximately evenly distributed among the active and remission subpopulations.
Analysis of variance revealed a significant difference between the GHb results for the subjects with active disease compared to those in remission or with benign tumors (P = .039). Analyzing the data for the active disease and remission groups using a nonparametric test (Mann-Whitney U) also confirmed the difference (P < .043). The finding of higher average blood glucose (GHb) in active disease patients is consistent with previous studies of hyperglycemia in cancer. [1] [2] [3] [4] [5] [6] Furthermore, the lower GHb in the subjects who had gained remission concurs with the 1 human study that reported a decline in GHb associated with neoplastic remission. Yetgin et al found that following treatment with the chemotherapeutic agent L-asparaginase, GHb values returned to normal with achievement of complete remission in children with acute lymphoblastic leukemia. 22 Consistent with the human studies, results in murine models showed that susceptibility to an aggressive mammary tumor was significantly influenced by blood glucose; 3 glucose levels (approximately 120, 100, and 80 mg/dL) were achieved by either sucrose in the ad lib water, a normal diet, or underfeeding, respectively. 19 With GHb elevated only 15% above normal (ie, 5.36 vs 4.67), the 10-week mortality due to the tumor was increased 200% above the mortality in normoglycemic animals. In addition, in hypoglycemic animals, with GHb decreased by 21% of normoglycemic (ie, 3.69 vs 4.67), mortality was only one sixth of the control mortality. The approximately 11% higher GHb seen in active disease patients corresponds to a difference in average blood glucose of about 15 mg/dL compared to those patients in remission. 23 Thus, it appears that in both animals and humans, even a modest lowering of blood glucose can greatly influence outcome in tumor disease.
Glycemic Control as an Adjunct to Cancer Therapy
Both diet and physical activity can influence glucose metabolism. A recent study in animals was specifically designed to examine the effects of a high glycemic index (GI) diet while controlling factors that have confounded other experiments (eg, fiber, palatability, and energy density). 24 Habitual consumption of high- GI meals (ie, those leading to large postprandial rises in blood glucose) was associated with a sequence of metabolic changes that could be relevant to cancer patients. A high-GI diet resulted in higher blood glucose and insulin in oral glucose tolerance tests compared to the low-GI diet. The aberrations in glucose control on the high-GI diet were associated with weight gain and higher body weight and body fat. 24 There are a number of aspects of fructose biology (eg, absorption, metabolism, effect on insulin release, and leptin secretion, etc) that may influence food intake and weight gain. 25 Not only has sweetened beverage intake increased in the past 30 years, but the form of sweetener has changed from predominantly sucrose to high-fructose corn syrup (HFCS). 25 Food products such as baked goods, canned fruits, jams and jellies, and dairy products are also now commonly sweetened with HFCS. The large increases in free (monosaccharide) fructose intake over these same decades are due primarily to the growth in HFCS use. 25 In the affluent nations, the 10-fold increase in consumption of HFCS over the past few decades has been suggested as a large contributor to the current epidemic of obesity in the United States. 25 In humans, weight gain after breast cancer diagnosis is associated with greater risks of relapse and death. 26 Thus, limiting intake of sweetened beverages and foods seems advisable.
In humans, low-GI diets can, within a few weeks, produce significant decreases in fasting blood glucose (15% decline) and GHb (~6% decline from a mean of 7.2 to 6.7). 27 Caloric restriction in primates and humans also improves glycemic control (eg, lowers insulin, fasting blood glucose, and GHb). 28, 29 Caloric restriction in adult humans can reduce fasting blood glucose by 21% and GHb by 15% within a few months. 28 Such modest reductions in average blood glucose were seen in our cancer patients, described above, who achieved remission and in the animals that demonstrated resistance to tumors. Thus, it appears that a lowering of blood glucose sufficient to improve outcomes in neoplastic disease should be achievable with adherence to a diet that reduces total calories and refined sugar intake and emphasizes low-GI foods.
The benefit of moderate carbohydrate intake on cancer survival was observed by Goodwin et al. 30 Extremes in diet were associated with poor survival in breast cancer patients. This was particularly evident for low protein intake (ie, 40 vs 80 g/d) and for high percentage of calories from carbohydrates (ie, greater than~40% of calories). Hazard ratios for survival were more than 2.5 at the extremes. This study did not distinguish between low-and high-GI carbohydrate foods. However, one might expect that in Western society diets, sugars and rapidly hydrolyzable forms of carbohydrate (eg, refined grains, potato, white rice, etc) rather than whole grains, legumes, and vegetable sources of carbohydrate would prevail in the highpercentage carbohydrate diets. A predominance of sugars and high-GI foods leads to deranged glucose metabolism. 24 Schneider et al summarized many ways in which exercise therapy can counteract side effects of cancer therapy and significantly improve quality of life in cancer patients. 31 There are reasons to speculate that survival would also be enhanced by increased exercise after cancer diagnosis. However, few studies have examined the relationship between physical activity and survival. One study found no effect, 32 whereas a recent report based on data from the large 30-year Nurses Health Study 33 found that a significant improvement in the chance of survival was related to increased physical activity. Women who exercised reduced their risk of dying by up to one half. It has been postulated that the lower estrogen levels related to physical activity contribute to the beneficial effects of exercise, especially for breast cancer. 34 Physical activity would also oppose weight gain after cancer diagnosis, which, as previously described, leads to poorer prognosis in breast cancer. Furthermore, exercise also improves glycemic control (eg, lowers GHb) in persons with elevated glucose. 35, 36 
AA and Cancer Therapy
Biochemical, clinical, and epidemiological evidence suggests that increased AA intake is associated with a reduced risk of chronic diseases. 37 In the older British population (ages 75-84 years), low blood AA levels are strongly predictive of mortality. 38 A small number of prospective studies have found a reduced cancer risk associated with increased AA intake or in some cases with increased plasma AA levels. 37 However, the recent analysis of a group of breast cancer patients treated with high levels of vitamins (including AA) and minerals failed to detect a benefit in survival or recurrence. 39 Hoffer 40 has commented on possible reasons for the apparent lack of positive outcomes in that study including the subset of patients selected, the control group, and certain uncontrolled variables.
Block and Mead reviewed the therapeutic use of AA and its influence on cancer survival. 41 Two doubleblind, placebo-controlled studies at the Mayo Clinic could not replicate the beneficial effects on survival, reduced pain, and quality of life reported by Cameron, Pauling, and others. Important distinctions between the Mayo Clinic and Cameron/Pauling protocols were pointed out. The latter used 10 g AA/day intravenous treatment for 10 days followed by 10 g AA orally for the life of the patient. The Mayo Clinic trials used only an oral 10 g AA/day dose and for limited times. On the basis of recent pharmacokinetic studies of AA, the peak plasma levels reached by intravenous administration would be~30 times greater than oral administration. 42 This calls into question the true comparability of the Cameron/Pauling and Mayo Clinic studies. Thus, the controversy over the benefit of AA in cancer therapy is still not settled.
There are many theoretical reasons to suggest AA as a beneficial adjunct to conventional cancer therapy. A chronic inflammatory condition often develops in patients with advanced cancer, causing oxidative stress. This stress can enhance lipid peroxidation 43 and can suppress immune functions, including those of T cells and natural killer cells. Ascorbate supplementation can increase resistance to both oxidative stress and lipid peroxidation. 43 AA can also stimulate the immune system by increasing T-lymphocyte proliferation and cytokine production. 44 Cancer patients treated with immunotherapy showed rapid depletion of plasma AA to nondetectable levels. 45 Only the patients who responded to therapy demonstrated some recovery of plasma AA. Optimizing AA intake thus appears warranted given AA's extreme safety both orally and intravenously.
Mechanism for the Beneficial Effects of Blood Glucose Control in Cancer
Although by no means unequivocal, considerable evidence does support a potential gain by elevating AA in prevention and treatment of cancer. The advantages of caloric restriction and exercise in prevention and survival are well documented. 13, 34 However, the mechanisms responsible for these benefits are unclear. 15 An explanation that incorporates both elevated AA and lowered blood glucose is a process termed the glucoseascorbate antagonism (GAA). [46] [47] [48] [49] According to this theory, dysfunction of immune response results, in large part, from lowered activity of the hexose monophosphate shunt (HMS), also called the pentose phosphate pathway. Cells involved in immune surveillance rely on the HMS for the respiratory burst and the generation of superoxide and hydrogen peroxide. 50 This is accomplished via nicotinamide adenine dinucleotide phosphate (NADPH), a direct product of the HMS. Another primary purpose of the HMS-derived NADPH is to maintain glutathione in its reduced functional state. 51 The reduced glutathione protects sulfhydryl groups within cells and, along with AA, helps preserve cellular integrity from oxidative stress. Immune cells function effectively only when intracellular AA levels and HMS activity are high.
Since the GAA mechanism was proposed, many additional details on AA, HMS, and blood glucose in relation to immune cells have been reported. In 1971, it was shown that the rate of HMS activity in phagocytic cells is markedly enhanced by increasing intracellular AA concentrations. 52 More recently, Puskus et al showed that dehydroascorbate (DHA, an oxidized form of AA) also strongly stimulates HMS activity. 51 AA and DHA enter cells by sodium-dependent and sodium-independent transporters, respectively. The sodium-independent glucose transporters (ie, GLUT 1 and GLUT 3) move DHA (as well as glucose) into cells from the blood. 53 Once inside cells, such as lymphocytes, DHA is rapidly converted to AA and contributes to stimulation of the HMS. 53 Increased AA supplementation can significantly elevate and maintain AA blood levels 42 and intracellular AA levels. 54 Compared to other tissues, lymphocytes preferentially take up AA from plasma (ie, there is a priority for maintenance of intracellular AA). 55 In vitro studies 56 and surveys of nonsupplementing adults 57 have shown that intracellular lymphocyte AA concentrations can be more than 50-fold greater than the plasma AA concentrations. Phagocytic activated neutrophils (ie, those treated with agents that stimulate the respiratory burst) accumulate intracellular AA at concentrations more than 10-fold higher than resting neutrophils. 58 The resting neutrophils already maintain an intracellular AA level 10-fold greater than plasma.
Elevated blood glucose opposes the cellular AA uptake process. In humans, a prompt in vivo lowering of intracellular AA in mononuclear leukocytes occurs as blood glucose increases. 59 Leucocyte AA fell by 50% within 10 to 20 minutes during intravenous glucose tolerance testing. The rapid fall in leukocyte AA was attributed to competitive inhibition by glucose of AA uptake. 60 A slowed phagocytic activity of neutrophils in vivo 61 and impaired function of human T cells in vitro occurs at elevated blood glucose levels. 62 In normal subjects, a glucose load that raised blood glucose to a moderate 120 mg/dL resulted in a 50% reduction in phagocytic index (ie, ability to engulf and destroy bacteria, etc); the slowed function persisted for more than 5 hours. 61 Intracellular AA is lower, and lymphocytes function poorly in diabetics; cytokine production, chemotaxis, adherence, phagocytosis, and intracellular killing activities are all significantly decreased. 63 Hyperglycemia and an inadequately functioning immune system, including decreased T cell proliferation and deficient production of T helper 1 cytokines, are often exhibited in patients and experimental animals with advanced cancer. These immune defects correlate with the severity of the disease and with poor survival. 64 The data from our subjects are consistent with the GAA theory. All the subjects showed similar AA intake and plasma levels but lower average blood glucose in the remission group (Table 1) . Moreover, a clinical study by Cheraskin et al is supportive of the theory. 18 In that study, patients undergoing radiation therapy for cervical carcinoma adopted a low sugar/low refined carbohydrate diet and received 1.2 g AA supplement daily. There was a significant difference in favorable radiation response achieved by these subjects compared to controls who did not modify their diets or receive supplements. In 1978 and 1979, 2 stage-4 breast cancer patients with large tumor burdens, worsening rapidly ("1 month" prognoses), although already on chemotherapy, elected to adopt a low-GI diet and~10 g AA/day. Both became tumor free in 6 months (reaching normal weight by losing an average of 50 pounds) and lived 11 and 13 years, respectively. 49 A limitation of our study was the lack of data on potentially confounding coexisting factors in our subjects such as diabetes, obesity, metabolic syndrome, and so forth that could influence glucose metabolism. Subjects with these conditions would tend to have higher GHbs and if more predominant in the active disease group, could have skewed the results. Inferences regarding the relative importance of hyperglycemia for different tumor types were not possible because of the small population size and diversity of malignancies present.
Conclusions
Cancer patients very frequently experience hyperglycemia. An elevated average plasma glucose (ie, GHb) has been associated with increased risk for cancer and cardiovascular disease. [65] [66] [67] However, very few data on average blood glucose (GHb) in patients achieving cancer remission are available. We observed a significant difference between GHb in the active disease and remission subjects in this relatively small group of patients. These results and many other in vitro, animal model, and human findings are consistent with the GAA theory.
Cancer patients exhibit numerous defects in immune competence that could contribute to increased susceptibility to infections and disease progression. Increased oxidative stress associated with a chronic inflammatory condition has been suggested as one of the causative mechanisms for the tumorinduced immune suppression. Antioxidant nutrients such as AA can oppose the oxidative stress.
It is attractive to speculate that modest AA supplementation, along with the lower blood glucoses attainable through reduced calorie and low-GI diets and exercise, might allow higher intracellular AA, produce a more effective immune response, and improve survival. Few conclusive studies of the influence of such nonclinical factors on cancer outcomes have been done. Low-fat diets are often recommended for cancer patients (especially for breast cancer). However, a decreased fat intake would increase the proportions of dietary protein and, more likely, carbohydrate. Many high-protein foods (eg, meat and dairy products) are also high in fat and would be restricted. It is plausible that a lower fat regimen could inadvertently increase carbohydrate intake and adversely affect glycemic control. Clinical trials currently evaluating the value of low-fat diets for cancer survival should clarify some of these uncertainties. 34 The use of GHb as a monitor of progress in cancer therapy may prove very useful. It is an inexpensive test that can be done in the nonfasting state. Its level has been shown to be correlated with risk for eye, kidney, and nerve disease in diabetics. Decreasing GHb through lifestyle changes and medication produces a decreased risk for these disorders. Recently, GHb has been shown to be an independent progressive risk factor for incident cardiovascular events, even in nondiabetics. 66 Gerstein has suggested that GHb be included in the list of other accepted indicators of cardiovascular risk such as blood pressure. 65 Thus, the utility of the GHb assay and the hazards of elevated plasma glucose in many disorders are continuing to assume greater prominence.
Extensive evidence that hyperglycemia is associated with poor clinical outcome in critically ill intensive care unit (ICU) patients has accumulated over the past decade. A definitive study by Krinsley using intensive blood glucose management in 800 consecutively admitted ICU patients demonstrated decreased mortality, organ dysfunction, and length of ICU stay. 68 Another study of critically ill surgical patients focused on antioxidant supplementation (eg, oral αtocopherol and intravenous AA). 69 This trial also showed striking reductions in mortality, organ failure, pulmonary morbidity, and length of ICU stay. Is it possible that these 2 recent studies were each highlighting only one half of the GAA mechanism (ie, hyperglycemia or insufficient AA)? Might the outcomes have been even more dramatic if both optimal AA and tight glucose control had been used concurrently? Similarly, could the lack of benefit from vitamin supplementation in cancer patients reported by Lesperance et al 39 or the failure of the Mayo Clinic AA cancer trials be related to neglect of the importance of blood glucose control?
In closing, data from our small group of subjects suggest that blood glucose is an important factor for recovery in cancer patients. Lifestyle changes in diet and physical activity to encourage a lowered GHb, to oppose weight gain, and to maximize the immunestimulating effects of AA should be considered as adjuncts to conventional cancer therapies.
